48,466
edits
Difference between revisions of "Clear cell renal cell carcinoma"
Jump to navigation
Jump to search
Clear cell renal cell carcinoma (view source)
Revision as of 05:00, 24 July 2014
, 05:00, 24 July 2014→IHC
(→IHC) |
|||
| Line 99: | Line 99: | ||
==IHC== | ==IHC== | ||
*CD10 +ve. | *CD10 +ve. | ||
** | *Vimentin +ve. | ||
*CK7 -ve. | |||
*CK20 -ve. | |||
===CCRCC versus [[chromophobe RCC]]=== | |||
ISUP recommends:<ref name=pmid25025364 >{{cite journal |author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' |title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=1017–22 |year=2014 |month=August |pmid=25025364 |doi=10.1097/PAS.0000000000000254 |url=}}</ref> | |||
*CD117 -ve (+ve in ChRCC). | |||
*CAIX (carbonic anhydrase CA IX) +ve (membranous).<ref name=pmid21677535>{{cite journal |author=Al-Ahmadie HA, Alden D, Fine SW, ''et al.'' |title=Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study |journal=Am. J. Surg. Pathol. |volume=35 |issue=7 |pages=949–61 |year=2011 |month=July |pmid=21677535 |doi=10.1097/PAS.0b013e31821e25cd |url=}}</ref> | |||
*CK7 -ve (+ve in ChRCC). | |||
Another set of stains:<ref name=pmid17683191>{{Cite journal | last1 = Liu | first1 = L. | last2 = Qian | first2 = J. | last3 = Singh | first3 = H. | last4 = Meiers | first4 = I. | last5 = Zhou | first5 = X. | last6 = Bostwick | first6 = DG. | title = Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. | journal = Arch Pathol Lab Med | volume = 131 | issue = 8 | pages = 1290-7 | month = Aug | year = 2007 | doi = 10.1043/1543-2165(2007)131[1290:IAOCRC]2.0.CO;2 | PMID = 17683191 }}</ref> | |||
*Vimentin +ve. | *Vimentin +ve. | ||
**-ve in ChRCC. | **-ve in ChRCC. | ||
*CD117 -ve. | *CD117 -ve. | ||
**+ve ~80% of ChRCC. | **+ve ~80% of ChRCC. | ||
===CCRCC versus [[CCPRCC]]=== | |||
ISUP recommends:<ref name=pmid25025364/> | |||
*CAIX +ve (strong membranous). | |||
*CK7 -ve. | |||
*AMACR -ve. | |||
Others: | Others: | ||
* | *CD10 +ve. | ||
* | **Usually -ve in [[clear cell papillary renal cell carcinoma]]. | ||
===CCRCC versus Xp11 translocation carcinomas=== | |||
ISUP recommends:<ref name=pmid25025364/> | |||
*Cathepsin K -ve.<ref name=pmid21602817>{{cite journal |author=Martignoni G, Gobbo S, Camparo P, ''et al.'' |title=Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions |journal=Mod. Pathol. |volume=24 |issue=10 |pages=1313–9 |year=2011 |month=October |pmid=21602817 |doi=10.1038/modpathol.2011.93 |url=}}</ref> | |||
*TFE3 -ve. | |||
*TFEB -ve. | |||
==Sign out== | ==Sign out== | ||